GO
Loading...

Pharmaceuticals

More

  • April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.

  • MUMBAI, April 18- India's Glenmark Pharmaceuticals Ltd is recalling some 2,900 bottles of its stomach ulcer drug ranitidine in the United States after a foreign tablet was found in one of the bottles.

  • Herbalife discloses investigation in Illinois Thursday, 17 Apr 2014 | 4:23 PM ET

    NEW YORK— Nutritional supplements and weight-loss products maker Herbalife is being investigated by the attorney general of Illinois. Herbalife says it will work with the attorney general's office, and that it is confident in the integrity of its business and its compliance with the law. Herbalife shares fell 17 cents to $55.10 on Thursday.

  • WASHINGTON, April 17- Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  • Teva willing to post $500 million bond in Copaxone case Thursday, 17 Apr 2014 | 3:18 PM ET

    WASHINGTON, April 17- Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  • April 17- Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. "helps them to get through 2014 with a lot less competition," Morningstar analyst Damien Conover said.

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent litigation with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster pain medication, Celebrex, in December. Celebrex's basic chemical patent expires on May 30.

  • NY-based co. closing Syracuse-area lab in July Thursday, 17 Apr 2014 | 7:53 AM ET

    CICERO, N.Y.— An Albany-based pharmaceutical company that's part of a $250 million economic development project in Buffalo is shutting down its Syracuse- area research center, eliminating 45 jobs. Albany Molecular Research Inc. announced Wednesday that it will close its 12- year-old facility in Cicero on July 15.

  • China backs away from price controls on basic drugs Thursday, 17 Apr 2014 | 7:02 AM ET

    BEIJING/ SHANGHAI, April 17- China has backtracked on its policy of capping retail prices on medicines and will allow pharmaceutical companies to set prices for some drugs, after criticism that controls had caused a drug drought that derailed treatment for millions of patients.

  • LONDON, April 17- Drugmaker GlaxoSmithKline- hit by bribery claims in five countries- is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices.

  • New kind of trial aims to speed cancer drug development Wednesday, 16 Apr 2014 | 7:01 PM ET

    *AstraZeneca, Pfizer, UK charity link in multi-drug trial. Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial.

  • Environmental groups slam Pa. smog proposal as lax Wednesday, 16 Apr 2014 | 4:48 PM ET

    The Sierra Club, the American Lung Association and other groups say that proposed emissions limits for coal-fired power plants are too lax. The biggest plants would be allowed to release more than 130,000 tons of smog-causing nitrogen oxides annually— 40 percent more than they do now, according to an analysis by the Sierra Club.

  • Illinois-based Astellas to pay $7.3M settlement Wednesday, 16 Apr 2014 | 3:17 PM ET

    NORTHBROOK, Ill.— The U.S. Justice Department announced Wednesday that an Illinois- based pharmaceutical company will pay $7.3 million to resolve allegations involving the marketing of the drug Mycamine. Northbrook- based Astellas Pharma US Inc. manufactures and sells Mycamine, which is used to treat invasive fungus infections.

  • Astellas to pay $7.3M in drug-marketing settlement Wednesday, 16 Apr 2014 | 2:42 PM ET

    NEW YORK— A unit of Japanese drugmaker Astellas Pharma will pay the U.S. government $7.3 million to resolve claims it illegally marketed its antifungal drug Mycamine for children before that use was approved. Another $3.1 million will go to state Medicaid programs. Medicaid did not cover Mycamine for children because the FDA had not yet approved that use.

  • April 16- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday, but combined sales of its nutritional products, medical devices and generic medicines were slightly below Wall Street expectations.

  • GlaxoSmithKline discloses new bribery inquiries Wednesday, 16 Apr 2014 | 12:25 PM ET

    NEW YORK— British drugmaker GlaxoSmithKline is looking into allegations of bribery within its operations in Jordan and Lebanon. On Monday the BBC reported that GlaxoSmithKline PLC is facing a bribery investigation in Poland, where a sales representative allegedly paid doctors to prescribe the company's asthma drug Seretide.

  • Judge blocks Massachusetts ban on painkiller Tuesday, 15 Apr 2014 | 3:06 PM ET

    BOSTON— A federal judge has blocked Massachusetts from banning the powerful new painkiller Zohydro. The judge issued a preliminary injunction Tuesday after pharmaceutical company, Zogenix, argued in a lawsuit that the ban issued by Gov.

  • Report: Prescription drug spending climbs in 2013 Tuesday, 15 Apr 2014 | 12:09 PM ET

    Total U.S. prescription drug spending climbed more than 3 percent last year, propelled in part by fewer patent expirations that would have allowed for cheaper generic alternatives, according to the data firm IMS Health. IMS Health also noted that 36 new treatments entered the market last year, including 10 for cancer.

  • April 15- Johnson& Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. J&J on Tuesday said it earned $4.73 billion, or $1.64 per share, in the first quarter.

Most Popular Video

Sunday, 20 Apr 2014 | 11:08 PM ET

Kelvin Tay, MD & Regional CIO for Southern APAC at UBS Wealth Management, expects U.S. firms to report 8 percent growth for 2014, but warns of risks from the recent winter freeze.

Sunday, 20 Apr 2014 | 10:47 PM ET

David Forrester, Senior Vice President, G10 FX Strategy at Macquarie, expects the Bank of Japan to unleash more stimulus ahead, which will spur further yen weakness.

Sunday, 20 Apr 2014 | 10:39 PM ET

James Chao, Director, Asia Pacific at IHS Automotive Consulting, addresses concerns surrounding the quality of vehicles made in China.